QPTF.F Stock Overview
A pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Quest PharmaTech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.013 |
| 52 Week High | CA$0.013 |
| 52 Week Low | CA$0.013 |
| Beta | 0.14 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -74.07% |
| 5 Year Change | -83.98% |
| Change since IPO | -67.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| QPTF.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 2.2% |
| 1Y | n/a | 16.2% | 31.7% |
Return vs Industry: Insufficient data to determine how QPTF.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how QPTF.F performed against the US Market.
Price Volatility
| QPTF.F volatility | |
|---|---|
| QPTF.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: QPTF.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine QPTF.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Madi Madiyalakan | www.questpharmatech.com |
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company’s lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for the potential cancer targets include pancreatic, colon, leukemia, ovarian, and breast cancer. It is also involved in the development of Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer.
Quest PharmaTech Inc. Fundamentals Summary
| QPTF.F fundamental statistics | |
|---|---|
| Market cap | US$3.69m |
| Earnings (TTM) | -US$2.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs QPTF.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QPTF.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.88m |
| Earnings | -CA$2.88m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.3% |
How did QPTF.F perform over the long term?
See historical performance and comparison